Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study

Dai, Ying‐Xiu; Wang, Shih-Chun; Chou, Yiing Jenq; Chang, Yao‐Feng; Chen, Tzeng Ji; Li, Chung–Pin; Wu, Chen‐Yi

doi:10.1016/j.jaad.2018.11.015

Cited by 60 publications

(50 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, benzo(a)pyrene‐induced CCL20 upregulation is synergistically enhanced by scratch injury . These findings may explain why smoking is an exacerbating factor for psoriasis …”

Section: Ccl20 Upregulation By Scratch Injury In Keratinocytesmentioning

confidence: 99%

“…As desquamative erythema can affect any site of skin, psoriasis profoundly impairs the patients' quality of life, treatment satisfaction and adherence, and socioeconomic stability . Skin injury and environmental factors such as smoking trigger or exacerbate psoriatic lesions . The development of psoriasis at sites of traumatized skin is called Koebner phenomenon .…”

Section: Introductionmentioning

confidence: 99%

“…[5][6][7][8][9] Skin injury and environmental factors such as smoking trigger or exacerbate psoriatic lesions. [10][11][12] The development of psoriasis at sites of traumatized skin is called Koebner phenomenon. 13 Genetic factors also play a crucial role in the development of psoriasis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The CCL20 and CCR6 axis in psoriasis

et al. 2019

View full text Add to dashboard Cite

Psoriasis is a TNF‐α/IL‐23/IL‐17A–mediated inflammatory skin disease that causes a significant socioeconomic burden in afflicted patients. IL‐17A–producing immune cells, including Th17 cells, are crucial effector cells in the development of psoriasis. IL‐17A stimulates epidermal keratinocytes to produce CCL20, which eventually recruits CCR6 + Th17 cells into the lesional skin. Thus, the CCL20/CCR6 axis works as a driving force that prepares an IL‐17A–rich cutaneous milieu. In this review, we summarize the current research topics on the CCL20/CCR6 axis and the therapeutic intervention of this axis for psoriasis.

show abstract

“…Notably, benzo(a)pyrene‐induced CCL20 upregulation is synergistically enhanced by scratch injury . These findings may explain why smoking is an exacerbating factor for psoriasis …”

Section: Ccl20 Upregulation By Scratch Injury In Keratinocytesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The CCL20 and CCR6 axis in psoriasis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This injury-induced development of psoriasis is called Koebner phenomenon [8,9]. Environmental factors, such as smoking, also trigger or exacerbate psoriatic lesions [10,11]. Genetic factors are critically involved in the development of psoriasis [12,13].…”

Section: Introductionmentioning

confidence: 99%

Interleukin-17A and Keratinocytes in Psoriasis

Furue

Tsuji

et al. 2020

IJMS

190

155

View full text Add to dashboard Cite

The excellent clinical efficacy of anti-interleukin 17A (IL-17A) biologics on psoriasis indicates a crucial pathogenic role of IL-17A in this autoinflammatory skin disease. IL-17A accelerates the proliferation of epidermal keratinocytes. Keratinocytes produce a myriad of antimicrobial peptides and chemokines, such as CXCL1, CXCL2, CXCL8, and CCL20. Antimicrobial peptides enhance skin inflammation. IL-17A is capable of upregulating the production of these chemokines and antimicrobial peptides in keratinocytes. CXCL1, CXCL2, and CXCL8 recruit neutrophils and CCL20 chemoattracts IL-17A-producing CCR6+ immune cells, which further contributes to forming an IL-17A-rich milieu. This feed-forward pathogenic process results in characteristic histopathological features, such as epidermal hyperproliferation, intraepidermal neutrophilic microabscess, and dermal CCR6+ cell infiltration. In this review, we focus on IL-17A and keratinocyte interaction regarding psoriasis pathogenesis.

show abstract

“…To protect individual privacy, the patients’ identification numbers were encrypted before the data was released to the researchers. The NHIRD has been widely used in many epidemiological studies 17–22 . This study was approved by the institutional review board of the Taipei Veterans General Hospital (2018‐07‐016AC).…”

Section: Methodsmentioning

confidence: 99%

Use of proton pump inhibitors and risk of rosacea: A nationwide population‐based study

Dai

Tai

Chen

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Proton pump inhibitors (PPI) are commonly used drugs. However, little is known about the association between PPI use and rosacea. This study aimed to investigate the association between PPI use and rosacea risk. Patients with prior PPI therapy, including 1067 rosacea cases and 4268 matched controls, were identified from the National Health Insurance Research Database in Taiwan. The cumulative defined daily dose (cDDD) was used to quantify the PPI use. Logistic regression was used for the analyses. After adjustment for potential confounders, PPI use with cDDD of more than 365 was significantly associated with an increased risk of rosacea (odds ratio [OR], 1.54; 95% confidence interval [CI], 1.10-2.15). Rosacea risk was significantly associated with PPI use of cDDD of more than 365 in women (OR, 1.62; 95% CI, 1.08-2.46) but not in men. Stratified by PPI indications, risk of rosacea was significantly associated with PPI use of cDDD of more than 365 for peptic ulcer (OR, 1.58; 95% CI, 1.12-2.21). In conclusion, prolonged PPI use was associated with an increased risk of rosacea, particularly in women and patients with peptic ulcers.

show abstract

Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study

Cited by 60 publications

References 33 publications

The CCL20 and CCR6 axis in psoriasis

The CCL20 and CCR6 axis in psoriasis

Interleukin-17A and Keratinocytes in Psoriasis

Use of proton pump inhibitors and risk of rosacea: A nationwide population‐based study

Contact Info

Product

Resources

About